Acrodermatitis continua Hallopeau successfully treated by risankizumab

Hugo, Jan; Gkalpakioti, Petra; Arenbergerová, Monika; Gkalpakiotis, Spyridon

doi:10.1111/ijd.15391

Cited by 3 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15 We have identified five case reports of patients with ACH treated with IL-12/23 inhibitors and four case reports of patients with ACH treated with IL-23 inhibitors in the literature, involving a total of twelve patients with ACH, as detailed in Table 1. 11,[16][17][18][19][20][21][22][23] Five patients were treated with Guselkumab, two with Risankizumab and five with Ustekinumab. Ustekinumab was reported to be effective, either as monotherapy or along with acitretin, 11,[20][21][22][23] but only one patient achieved a satisfactory clinical response at the recommended dose and frequency.…”

Section: Discussionmentioning

confidence: 99%

Acrodermatitis Continua of Hallopeau Successfully Treated with Ustekinumab: A Case Report and Literature Review

Shi¹,

Zeng²,

Huang³

et al. 2023

CCID

View full text Add to dashboard Cite

Acrodermatitis continua of Hallopeau (ACH) is a rare variant of pustular psoriasis that presents as a sterile pustular eruption of the periungual and subungual regions. It affects the skin and nail bed and can lead to distal phalangeal destruction as the disease progresses. ACH is an incurable disease that requires long-term maintenance therapy to prevent any complications. Because ACH is a variant of pustular psoriasis, it is commonly treated with anti-psoriatic therapies. Unfortunately, it is resistant to many available anti-psoriatic therapies, and there are no clinical guidelines for it; the treatment is therefore highly challenging. Current treatment strategies are mostly based on a few case reports and case series. In this study, we present a case of ACH in a 24-year-old man with a long history of severe skin lesions and overt onychodystrophy, successfully treated with Ustekinumab. In this patient, we observed rapid improvement in skin lesions and symptoms. Ustekinumab can considerably improve other symptoms besides plaque psoriasis. The treatment and excellent outcomes of Ustekinumab may provide clinical benefits to more patients and serve as a reference for other dermatologists.

show abstract

Section: Discussionmentioning

confidence: 99%

Acrodermatitis Continua of Hallopeau Successfully Treated with Ustekinumab: A Case Report and Literature Review

Shi¹,

Zeng²,

Huang³

et al. 2023

CCID

View full text Add to dashboard Cite

show abstract

“…There are numerous reported cases of ACH successfully treated with biologic agents such as anti-IL-17 (secukinumab, ixekizumab), 4,5 anti-IL12/23 (ustekinumab 5 ), anti-TNF-α (infliximab, etanercept, adalimumab) 4,5 and IL-23 inhibitors (in particular three patients with guselkumab, 4,6 two patients with risankizumab 6,7 ). We report the case guselkumab may result in inhibiting pathogenic Th17 cells and consequently downstream production of multiple effector cytokines.…”

mentioning

confidence: 99%